<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: We have previously demonstrated the therapeutic usefulness of leptin in lipoatrophic <z:mp ids='MP_0002055'>diabetes</z:mp> and insulin-deficient <z:mp ids='MP_0002055'>diabetes</z:mp> in mouse models and could also demonstrate its dramatic effects on lipoatrophic <z:mp ids='MP_0002055'>diabetes</z:mp> in humans </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the present study was to explore the therapeutic usefulness of leptin in a mouse model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with <z:mp ids='MP_0010024'>increased adiposity</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: To generate a mouse model mimicking human type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with <z:mp ids='MP_0010024'>increased adiposity</z:mp>, we used a combination of low-dose <z:chebi fb="1" ids="9288">streptozotocin</z:chebi> (STZ, 120 microg/g body weight) and high-fat diet (HFD, 45% of energy as fat) </plain></SENT>
<SENT sid="3" pm="."><plain>Recombinant mouse leptin was infused chronically (20 ng [g body weight](-1) h(-1)) for 14 days using a mini-osmotic pump </plain></SENT>
<SENT sid="4" pm="."><plain>The effects of leptin on food intake, body weight, metabolic variables, tissue triacylglycerol content and <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase (AMPK) activity were examined </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Low-dose STZ injection led to a substantial reduction of plasma insulin levels and <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Subsequent HFD feeding <z:mp ids='MP_0010024'>increased adiposity</z:mp> and induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and further augmentation of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In this model mouse mimicking human type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (STZ/HFD), continuous leptin infusion reduced food intake and body weight and improved <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism with enhancement of insulin sensitivity </plain></SENT>
<SENT sid="8" pm="."><plain>Leptin also decreased liver and skeletal muscle triacylglycerol content accompanied by an increase of alpha2 AMPK activity in skeletal muscle </plain></SENT>
<SENT sid="9" pm="."><plain>Pair-feeding experiments demonstrated that leptin improved <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism independently of the food intake reduction </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: This study demonstrates the beneficial effects of leptin on glycaemic and <z:chebi fb="23" ids="18059">lipid</z:chebi> control in a mouse model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with <z:mp ids='MP_0010024'>increased adiposity</z:mp>, indicating the possible clinical usefulness of leptin as a new <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering drug in humans </plain></SENT>
</text></document>